TransMedics Group (NASDAQ:TMDX) Reaches New 12-Month Low – Here’s What Happened

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) reached a new 52-week low on Thursday . The stock traded as low as $57.90 and last traded at $58.02, with a volume of 2203853 shares traded. The stock had previously closed at $60.44.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. TD Cowen dropped their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Robert W. Baird reduced their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Finally, Piper Sandler dropped their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Stock Performance

The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 61.72 and a beta of 2.12. The stock has a 50-day moving average price of $72.63 and a 200 day moving average price of $119.17.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the business posted ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% on a year-over-year basis. As a group, analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently bought and sold shares of the company. USA Financial Formulas acquired a new position in TransMedics Group during the third quarter worth $55,000. Quarry LP lifted its position in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after buying an additional 312 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after buying an additional 262 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares in the last quarter. Finally, Rakuten Securities Inc. bought a new position in shares of TransMedics Group in the 3rd quarter valued at about $126,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.